<<
[an error occurred while processing this directive]
|
[an error occurred while processing this directive]
>>
������ͪ�ԷǾƾ���֬���Ըβ�����Ѫ���ֿ������ȵ��صֿ���Ӱ��
�ɽ��� 1 ��Ҷ���� 2
LIANG Jiang-hong1 �� YE Jian-hong2
�� 1. <>First Hospital Affiliated Nanchang University, Nanchang 330006,<> China; 2.<>Foshan Traditional Chinese Medicine Hospital Guangzhou Chinese Traditional Medicine University, Foshan 528000,<> China
Abstract��
OBJECTIVE To investigate the effect of pioglitazone on resistin levels and insulin resistance(IR) in subjects with nonalcoholic fatty liver disease (NAFLD). METHODS 136 Subjects aged from 30 to 65 years with NAFLD were divided into two groups. One group received pioglitazone treatment as treatment group and the other received placebo treatment as placebo group.The diagnostic criteria were according to the recommendation of NAFLD given by Chinese Medical Association in 2003. 50 healthy adult subjects were assigned in control group. All subjects received pioglitazone 30 mg once daily for 12 weeks. Before and after treatment, insulin resistance was calculated by HOMR-IR and blood rersistin levels were measured by ELISA. RESULTS ��WC, BMI, FPG, FINS, TG, ALT, AST, HOMA-IR and plasma resistin levels in NAFLD group were significantly higher than in control group. HDL-C in NAFLD group was significantly lower than those in control group. ��HOMA-IR in NAFLD group was associated with WC, BMI, TG, HDL-C, FINS and plasma resistin levels( all P<0.05). Stepwise multiple regression analysis revealed that rersistin and WC were the independent related factors of HOMA-IR. ��After 12 weeks treatment of pioglitazone, FPG, FINS, ALT, AST, HOMA-IR and resistin levels in NAFLD subjects decreased significantly. CONCLUSIONS Plasma resistin levels and HOMA-IR in subjects with NAFLD were significantly higher than those in controls. Increased resistin levels were probably associated with IR. In subjects with NAFLD pioglitazone treatment improved insulin sensitivity and decreased plasma resistin levels significantly. Suggesting the mechanism of pioglitazon effect on insulin sensitivity may be related to decreased plasma resistin levels.
LIANG Jiang-hong,
YE Jian-hong
. Effects of Pioglitazone on Plasma Resistin Levels and Insulin Resistance in Patients with Nonalcoholic Fatty Liver Disease[J] Chinese Pharmaceutical Journal, 2009,V44(24): 1900-1903
��
[1]
MA X, LI Z. Pathogenesis of nonalcoholic steatohepatitis (NASH)[J]. <>Chin J Dig Dis( �л�������־ ), 2006;7(1):7-11.
[2]
ALMEDA-VALD��S P, CUEVAS-RAMOS D. Aguilar-Salinas C A . Metabolic syndrome and non-alcoholic fatty liver disease[J]. <>Ann Hepatol, 2009, 8(Suppl 1): S18-24.
[3]
KHASHAB M, CHALASANI N, <>et al. Use of insulin sensitizers in NASH[J]. <>Endocrinol Metab Clin North Am, 2007, 36(4):1067-1087.
[4]
DAY C P, JAMES O F W. Steatohepatitis-a tale of two ��hits��? [J]. <>Gastroenterology, 1998, 114(4):842-845.
[5]
DEGAWA-YAMAUCHI M, BOVENKERK J E, JULIAR B E, <>et al. Serum resistin (FIZZ3) protein is increased in obese humans[J]. <>J Clin Endocrinol Metab, 2003, 88(11): 5452-5455.
PCHALASANI N P, SANYAL A J, KOWDLEY K V, <>et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design [J]. <>Contemp Clin Trials, 2009, 30(1):88-96.
2009, Vol. 44 
